概括
患有抑郁症的患者表现出相结合胺的减少,这表明单胺氧化酶 (MAO) 的增加. 活动.活动.活动. 这种酶可能会代谢更多的氨酸,从而降低抑郁症中的结合水平.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 单胺氧化酶 (M.A.O.) 是一种 抑制剂是抗抑郁药的一类.
- 提拉胺代谢与MAO有关. 活动.活动.活动.
- 抑郁症与神经递质系统的改变有关.
研究的目的:
- 为了研究抑郁症患者的提拉胺代谢.
- 为了比较抑郁症患者与对照患者的结合胺输出.
- 探索M.A.O.的作用 与抑郁症相关的氨基代谢中的活性.
主要方法:
- 对抑郁症患者和正常对照进行的口服提拉胺和异上腺素负荷.
- 测量并比较了结合胺和异二烯的输出.
- 评估的患者接受或适合M.A.O.治疗. 抑制剂治疗. 抑制剂治疗.
主要成果:
- 与对照组相比,抑郁症患者的结合胺产量显著降低.
- 两组之间没有发现合性异上腺素输出的显著差异.
- 观察到的提拉胺结合的缺陷表明功能性MAO的增加. 活动.活动.活动.
结论:
- 这些发现表明MAO的增加. 在抑郁症中的活性,导致提拉胺代谢发生变化.
- 这种增加的活性可能解释了氨酸的合体池的减少.
- 对M.A.O.进行进一步的研究. 在抑郁症中的功能是合理的.
相关概念视频
G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...


